Page last updated: 2024-10-24

NAD biosynthesis via nicotinamide riboside salvage pathway

Definition

Target type: biologicalprocess

The chemical reactions and pathways resulting in the formation of nicotinamide adenine dinucleotide (NAD) from the vitamin precursor nicotinamide riboside. [PMID:17482543]

NAD biosynthesis via nicotinamide riboside salvage pathway is a critical metabolic route for generating nicotinamide adenine dinucleotide (NAD+), a vital coenzyme involved in numerous cellular processes, including energy production (via oxidative phosphorylation), DNA repair, and signal transduction. This pathway utilizes nicotinamide riboside (NR), a naturally occurring NAD+ precursor, as its substrate.

The pathway commences with the uptake of NR from the extracellular environment or intracellular sources. NR is then transported into the cytoplasm, where it encounters the enzyme nicotinamide riboside kinase (NRK). NRK catalyzes the phosphorylation of NR to nicotinamide mononucleotide (NMN), using ATP as a phosphate donor.

NMN serves as the substrate for the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT), which catalyzes the final step in NAD+ biosynthesis from NR. NMNAT utilizes ATP to adenylylate NMN, yielding NAD+. This reaction occurs predominantly in the nucleus, where NAD+ is required for various nuclear functions.

The nicotinamide riboside salvage pathway is highly efficient and provides a significant contribution to the cellular NAD+ pool. Notably, NR is readily absorbed from the diet and can be synthesized in various tissues, contributing to the pathway's importance in maintaining cellular NAD+ homeostasis.

In addition to its role in NAD+ biosynthesis, the nicotinamide riboside salvage pathway also plays a crucial role in regulating cellular NAD+ levels. The pathway is tightly regulated by the availability of NR, the activity of NRK and NMNAT, and the cellular NAD+ demand.

Overall, the nicotinamide riboside salvage pathway is a fundamental metabolic process that ensures adequate NAD+ levels for various cellular functions. This pathway is essential for maintaining cellular health and has gained significant attention for its potential therapeutic implications in various diseases, including aging and neurodegenerative disorders.'
"

Proteins (12)

ProteinDefinitionTaxonomy
Protein mono-ADP-ribosyltransferase PARP16A protein mono-ADP-ribosyltransferase PARP16 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8N5Y8]Homo sapiens (human)
Protein mono-ADP-ribosyltransferase PARP9A protein mono-ADP-ribosyltransferase PARP9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8IXQ6]Homo sapiens (human)
Protein mono-ADP-ribosyltransferase PARP10A protein mono-ADP-ribosyltransferase PARP10 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q53GL7]Homo sapiens (human)
Prostacyclin synthaseA prostacyclin synthase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16647]Homo sapiens (human)
Nicotinamide phosphoribosyltransferaseA nicotinamide phosphoribosyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P43490]Homo sapiens (human)
Nicotinamide N-methyltransferaseA nicotinamide N-methyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P40261]Homo sapiens (human)
Protein mono-ADP-ribosyltransferase PARP16A protein mono-ADP-ribosyltransferase PARP16 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8N5Y8]Homo sapiens (human)
Protein mono-ADP-ribosyltransferase PARP9A protein mono-ADP-ribosyltransferase PARP9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8IXQ6]Homo sapiens (human)
Protein mono-ADP-ribosyltransferase PARP10A protein mono-ADP-ribosyltransferase PARP10 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q53GL7]Homo sapiens (human)
Prostacyclin synthaseA prostacyclin synthase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16647]Homo sapiens (human)
Nicotinamide phosphoribosyltransferaseA nicotinamide phosphoribosyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P43490]Homo sapiens (human)
Nicotinamide N-methyltransferaseA nicotinamide N-methyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P40261]Homo sapiens (human)

Compounds (37)

CompoundDefinitionClassesRoles
benzamidebenzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.benzamides
ci 994tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.

tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells
acetamides;
benzamides;
substituted aniline
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
diazoxidediazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.

Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
benzothiadiazine;
organochlorine compound;
sulfone
antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
pj-34PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties.phenanthridines;
secondary carboxamide;
tertiary amino compound
angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent
1,2,3,4-tetrahydroisoquinoline1,2,3,4-tetrahydroisoquinoline: RN given refers to cpd with locants as specifiedisoquinolines
quinolineazaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinolines
isoquinolineazaarene;
isoquinolines;
mancude organic heterobicyclic parent;
ortho-fused heteroarene
6-aminonicotinamide6-aminonicotinamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 6-aminonicotinic acid with ammonia. An inhibitor of the NADP(+)-dependent enzyme, 6-phosphogluconate dehydrogenase, it interferes with glycolysis, resulting in ATP depletion and synergizes with DNA-crosslinking chemotherapy drugs, such as cisplatin, in killing cancer cells.

6-Aminonicotinamide: A vitamin antagonist which has teratogenic effects.
aminopyridine;
monocarboxylic acid amide;
primary amino compound
antimetabolite;
EC 1.1.1.44 (NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase) inhibitor;
teratogenic agent
dazoxibendazoxiben: RN given refers to parent cpd
dazmegrel
pirmagrelpirmagrel: structure given in first source
sinefunginadenosines;
non-proteinogenic alpha-amino acid
antifungal agent;
antimicrobial agent
n'-methyl-2-pyridone-5-carboxamideN-methyl-6-pyridone-3-carboxamide : A pyridone that is 2-pyridone substituted with a carboxamide group at C-5 and a methyl group at N-1.

N'-methyl-2-pyridone-5-carboxamide: structure
methylpyridines;
pyridinecarboxamide;
pyridone
metabolite;
mouse metabolite
4-Methoxybenzamidebenzamides
3,4-dihydro-5-methyl-1(2h)-isoquinolinone3,4-dihydro-5-methyl-1(2H)-isoquinolinone: structure given in first sourceisoquinolines
chs 828aromatic ether
1-oxo-1,2,3,4-tetrahydroisoquinoline1-oxo-1,2,3,4-tetrahydroisoquinoline: structure given in first source
n(4)-adenosyl-n(4)-methyl-2,4-diaminobutanoic acid
uk 34787UK 34787: RN given refers to parent cpd
s-adenosylhomocysteineS-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine.

S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions.
adenosines;
amino acid zwitterion;
homocysteine derivative;
homocysteines;
organic sulfide
cofactor;
EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor;
EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor;
epitope;
fundamental metabolite
thionicotinamide
stf-31STF-31: antineoplastic
isbogrel
fk 866N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first sourcebenzamides;
N-acylpiperidine
rucaparibAG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first sourceazepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound
antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
latonduine alatonduine A: structure in first source
veliparibbenzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
chidamidebenzamides
quinoline-3-carboxamidequinoline-3-carboxamide: structure in first source
olaparibcyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines
antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
niraparibniraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.

niraparib: structure in first source
2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamideantineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent
pf 9184
gne-618GNE-618: inhibits nicotinamide phosphoribosyl transferase; structure in first source
g007-lkG007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source
gne-617GNE-617: inhibits nicotinamide phosphoribosyltransferase; structure in first source
xav939XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.

XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source
(trifluoromethyl)benzenes;
thiopyranopyrimidine
tankyrase inhibitor
bmn 673talazoparib: inhibits both PARP1 and PARP2; structure in first source